Notch signaling control tools to tailor cell signaling
Official title: Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering supplement
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11468159 · Data updated 2026-11-12
A patient-focused window into how researchers are creating safe, targeted ways to turn Notch signaling on or off in specific tissues to help stem cell and immune-related conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 1, 2019 |
| Project end | January 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $89,222 |
| NIH project number | 3R35GM133482-07S1 |
| Project ID | NIH-11468159 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients whose conditions relate to stem cell development or immune signaling where targeted Notch modulation could be beneficial in the future.
✕Less likely to help
Patients not connected to stem cell or immune pathway contexts may not directly benefit from this basic research.
What this research studies
This project uses structure-guided protein engineering to reprogram how cells respond to Notch signaling, aiming to create tissue-specific activators or inhibitors. The work focuses on understanding the structural basis of receptor-ligand interactions and how changes in these contacts alter cellular outcomes. The team is developing biotechnological tools to precisely modulate signaling in different tissue contexts, with potential applications in regenerative medicine and immune-related conditions. Research also includes studying how Notch communicates with other developmental pathways and identifying ligands that influence these signals. Overall, the goal is to translate structural insights into customizable signaling outputs that could benefit patients in the future.
Why it matters
Potential benefit: If successful, this work could lead to new ways to guide stem cell development and immune responses in patients.
How similar studies have gone: Previous work has shown that structural engineering can modulate receptor signaling, supporting the potential for meaningful progress here.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Luca, Vince — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Luca, Vince
Related research
Other NIH-funded projects on the same topics.
-
Central Laboratory Core for Advanced Cancer Research
A central laboratory core provides shared, specialized services to cancer researchers to help advance patient-focused studies.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Administration & Coordinating Core
This grant funds a central hub to help coordinate cancer research efforts at a major cancer center so researchers can work together more efficiently.
-
Developmental and Career Enhancement Core (for researchers)
A dedicated program to help researchers build skills and advance their careers over several years.
-
Central Laboratory Core for Cancer Research
A cancer research center is funding a shared lab core to support various studies over the next five years.
-
Exploring how HPV-related cancers affect people living with HIV and what helps survival
A patient-friendly look at a project studying how HPV-related cancers and HIV interact and what factors influence survival.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.